|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-3-17
|
|
pubmed:abstractText |
Human interleukin-21 (IL-21) is a class I cytokine that mediates activation of CD8(+) T cells, natural killer (NK) cells, and other cell types. We report final clinical and biological results of a phase II study of recombinant human IL-21 (rIL-21) in patients with metastatic melanoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:BradyBenB,
pubmed-author:CebonJonathanJ,
pubmed-author:DavisIan DID,
pubmed-author:FrederiksenKlaus StensgaardKS,
pubmed-author:HansenLasse TengbjergLT,
pubmed-author:KeffordRichard FRF,
pubmed-author:KristjansenPaul E GPE,
pubmed-author:LundsgaardDortheD,
pubmed-author:McArthurGrantG,
pubmed-author:MillwardMichaelM,
pubmed-author:MouritzenUlrikU,
pubmed-author:SkakKrestenK,
pubmed-author:SkrumsagerBirte KBK
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2123-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19276257-Adult,
pubmed-meshheading:19276257-Aged,
pubmed-meshheading:19276257-Female,
pubmed-meshheading:19276257-Humans,
pubmed-meshheading:19276257-Interleukin-2 Receptor alpha Subunit,
pubmed-meshheading:19276257-Interleukins,
pubmed-meshheading:19276257-Male,
pubmed-meshheading:19276257-Melanoma,
pubmed-meshheading:19276257-Middle Aged,
pubmed-meshheading:19276257-Neoplasm Staging,
pubmed-meshheading:19276257-Recombinant Proteins,
pubmed-meshheading:19276257-T-Lymphocyte Subsets
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.
|
|
pubmed:affiliation |
Ludwig Oncology Unit, Austin Health, Melbourne, Victoria, Australia.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
